Medicare Enrolled

Dr. Thomas Leblanc, MD, MA

Medical Oncology · Durham, NC
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
40 DUKE MEDICINE CIR, Durham, NC 27710
9196848111
In practice since 2007 (19 years)
NPI: 1790997989 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Leblanc from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Leblanc? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Leblanc

Dr. Thomas Leblanc is a medical oncology specialist in Durham, NC, with 19 years of NPI registration. Based on federal Medicare data, Dr. Leblanc performed 229 Medicare services across 77 unique beneficiaries.

Between the years covered by Open Payments, Dr. Leblanc received a total of $1,306,417 from 35 pharmaceutical and/or device companies across 1042 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Leblanc is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ 229 Medicare services $1,306,417 industry payments

Medicare Practice Summary

Medicare Utilization ↗
229
Medicare services
Bottom 33% in NC for medical oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
77
Unique beneficiaries
$97
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~12 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
117 $93 $282
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
100 $98 $447
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
12 $132 $582
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$1,306,417
Total received (2018-2024)
Avg $186,631/year across 7 years
Top 0% in NC for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
35
Companies
1,042
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,037,380 (79.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$266,566 (20.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,471 (0.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$316,012
2023
$274,543
2022
$240,282
2021
$162,080
2020
$177,086
2019
$97,483
2018
$38,930

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$108,106
ABBVIE INC.
$69,043
Incyte Corporation
$47,950
Rigel Pharmaceuticals, Inc.
$36,465
SERVIER PHARMACEUTICALS LLC
$19,857
PFIZER INC.
$8,390
Novartis Pharmaceuticals Corporation
$6,341
Eli Lilly and Company
$5,400
Stemline Therapeutics Inc.
$3,959
Gilead Sciences, Inc.
$3,840
Genentech USA, Inc.
$3,040
Celgene Corporation
$1,890
GlaxoSmithKline, LLC.
$1,200
TAIHO ONCOLOGY, INC.
$267
Astellas Pharma US Inc
$118
JAZZ PHARMACEUTICALS INC.
$98
Daiichi Sankyo Inc.
$50
Top 3 companies account for 71.2% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$381,139
ABBVIE INC.
$211,115
Celgene Corporation
$195,064
Incyte Corporation
$87,254
Agios Pharmaceuticals, Inc.
$81,536
SERVIER PHARMACEUTICALS LLC
$57,795
AbbVie Inc.
$46,091
Rigel Pharmaceuticals, Inc.
$45,503
PFIZER INC.
$25,568
Servier Pharmaceuticals LLC
$24,953
AstraZeneca Pharmaceuticals LP
$24,252
Astellas Pharma US Inc
$23,838
Genentech USA, Inc.
$15,444
Daiichi Sankyo Inc.
$12,747
Eli Lilly and Company
$11,700
Amgen Inc.
$11,416
Novartis Pharmaceuticals Corporation
$9,955
Heron Therapeutics, Inc.
$6,662
AbbVie, Inc.
$6,291
GlaxoSmithKline, LLC.
$5,750
Stemline Therapeutics Inc.
$3,959
Seattle Genetics, Inc.
$3,915
Gilead Sciences, Inc.
$3,840
Otsuka Pharmaceutical Development & Commercialization, Inc.
$3,038
AstraZeneca UK Limited
$1,712
Astellas Pharma Global Development
$1,300
Janssen Scientific Affairs, LLC
$1,262
Acceleron Pharma, Inc.
$1,000
NOVARTIS PHARMACEUTICALS CORPORATION
$800
Genentech, Inc.
$550
BeiGene, Ltd.
$450
TAIHO ONCOLOGY, INC.
$267
Adaptive Biotechnologies Corporation
$122
JAZZ PHARMACEUTICALS INC.
$113
Jazz Pharmaceuticals Inc.
$13
Top 3 companies account for 60.3% of all-time payments
Associated products mentioned in payments ›
BLENREP · BRUKINSA · CALQUENCE · CINVANTI · DAURISMO · ELREXFIO · ELZONRIS · IMBRUVICA · INQOVI · Idhifa · JAKAFI · Kyprolis · LORBRENA · ONCASPAR · ONUREG · Orserdu · REBLOZYL · Reblozyl · Revlimid · Rezlidhia · SPRYCEL · TAGRISSO · TASIGNA · TIBSOVO · Tibsovo · VENCLEXTA · VYXEOS · Vanflyta · Venclexta · XOSPATA · Xospata · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (79%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for medical oncology in NC.

Looking for a medical oncology specialist in Durham?
Compare medical oncologists in the Durham area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Leblanc is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 0% of NC peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Leblanc experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Leblanc performed 117 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Leblanc receive payments from pharmaceutical companies?
Yes. Dr. Leblanc received a total of $1,306,417 from 35 companies across 1,042 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Leblanc's costs compare to other medical oncologists in Durham?
Dr. Leblanc's average Medicare payment per service is $97. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Leblanc) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →